Regulatory Opportunities and Challenges in Europe:

A proposal from the Italian Experience on Registries

Luca Pani, M.D.
Director General, Italian Medicines Agency
CHMP, SAWP Member, European Medicine Agency

DG@aifa.gov.it  @Luca__Pani
Public Declaration of transparency/interests*

The view and opinions expressed are those of the individual presenter and should not be attributed to AIFA/EMA

*Luca Pani, in accordance with the Revised Conflict of Interest Regulations approved by AIFA Board of Directors (25.03.2015) and published on the Official Journal of 15.05.2015 according to EMA policy /626261/2014 on the handling of the conflicts of interest for scientific committee members and experts. For this talk I receive NO compensation.

<table>
<thead>
<tr>
<th>Interests in pharmaceutical industry</th>
<th>NO</th>
<th>Current</th>
<th>From 0 to 3 previous years</th>
<th>Over 3 previous years</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DIRECT INTERESTS:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.1 Employment with a company: pharmaceutical company in an executive role</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.2 Employment with a company: in a lead role in the development of a medicinal product</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.3 Employment with a company: other activities</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Consultancy for a company</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Strategic advisory role for a company</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Financial interests</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Ownership of a patent</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>INDIRECT INTERESTS:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Principal investigator</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Investigator</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. Grant or other funding</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. Family members interests</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Most important challenges for Regulators / Payers

- How do we achieve better outcomes and control the cost curve?

- Ageing demographics
- Sustainability
- Healthcare cost inflation
- Technology advances
- Rising patient expectations
- Rising chronic diseases
- Unhealthy lifestyles
- Health inequalities

- Rising patient expectations
- Rising chronic diseases
- Unhealthy lifestyles

- Technology advances
- Sustainability
- Healthcare cost inflation

- Ageing demographics
Bridging the efficacy–effectiveness gap

Patients are not equally responsive to beneficial effects, and not equally susceptible to AEs.

Regulatory decisions are based on population-level information, with an understanding that the B-R will not necessarily be positive for all treated patients.
The Italian Medicines Agency Strategy

Clinical development

Market entry

Real world effectiveness and safety

Further regulatory/policy actions

Early dialogue/scientific advice

Conditional Reimbursement (MEAs)

Monitoring Registries

Re-assessment
MONITORING REGISTRIES AT ITALIAN MEDICINES AGENCY: FOSTERING ACCESS, GUARANTEEING SUSTAINABILITY

Simona Montilla  
Italian Medicines Agency (AIFA)  
S.Montilla@aifa.gov.it

Emelio Xoxi, Pierluigi Russo  
Italian Medicines Agency (AIFA)

Americo Circhetti  
Università Cattolica del Sacro Cuore

Luca Papi  
Italian Medicines Agency (AIFA)

Objectives: The AIFA (Agenzia Italiana del Farmaco—Italian Medicines Agency) Monitoring Registries track the eligibility of patients and the complete flow of treatments, guaranteeing appropriateness in use of pharmaceutical products, according to approved indications.

Methods: This study describes the Italian pharmaceutical context and the aims and functioning of AIFA Monitoring Registries, focusing on the applications to the Managed Entry Agreements (MEAs) and HTA approaches.

Results: The AIFA Monitoring Registries System has been operational in Italy since 2005. In 2012, the system became part of the NHS Information Technology system, aiming at enhancing appropriate use of pharmaceuticals and efficiency of the administrative activity. Currently, seventy-six medicines are monitored through the system, corresponding to fifty-eight therapeutic indications; individual treatments recorded are more than 515,000, for a population of approximately 505,000 patients. For each monitored product, patients eligible for treatment are registered in the specific therapeutic indication dynamic monitoring database to collect epidemiologic and clinical data, including data on the safety profile, and expost information missing at first evaluation stage.

Conclusions: AIFA Monitoring Registries allow the evaluation of the pharmaceuticals’ performance in clinical practice and may promote innovation and quicker access to medicines at affordable prices, for the benefit of patients.

Keywords: Drug monitoring, Registries, Real clinical practice data collection, Managed entry agreements
Registries provide Real World Data (RWD)

RWD is an umbrella term including effects of health interventions that are not collected in the context of conventional RCTs.

Registries are one of the main sources of RWD.

Alternative / Additional tools are:

- Electronic medical records
- Observational studies
- Administrative data
- Claims databases
- Health surveys & patient reported outcomes (PROs).
AIFA Monitoring Registries are...

AIFA drug-product Registries are web tools placed in the early phases after MA and also for some “authorized” off label use.

In 2012 AIFA Registries officially became part of the NHS Information Technology (IT) Law n. 135/2012.

Measure RW safety and effectiveness and Apply MEAs procedures.
The Italian Medicines Agency Strategy: A range of Managed Entry Agreements (MEAs)

- Refusal
- Reimbursement (without conditions)
- Managing budget impact
- Managing uncertainty relating to clinical benefit and cost-effectiveness
- Managing utilisation to optimize performance

Non-Outcome based MEAs:
- Volume agreements
- Cost sharing
- Budget cap

Monitoring registers:
- Oncologicals
- Orphans
- Psoriasis
- Antidiabetics
- Cardiovascular
- Antireumatics

Outcome based MEAs:
- Payment by results
- Risk sharing

Therapeutic plan
AIFA notes
When New Cancer Treatments Fail, Italy Wants Its Money Back

The Italian Medicines Agency has devised deals with pharma companies that set payment based on how well a patient responds to treatment, and in some cases where the medication fails to help, the drugmaker gives a full refund. Italy is signing more such contracts as growing numbers of medications receive regulatory approval after mid-stage trials of fewer than 100 patients rather than awaiting final-stage assessments involving thousands.

Drug contracts with money-back guarantees
Italy is signing more contracts stipulating refunds when treatments fail, allowing it to take a chance on medicines getting approved with smaller trials
80 of 96 Registries are associated with a MEA; PbR are the most frequently used schemes.


Managed entry agreements for pharmaceuticals: the European experience
Alessandra Ferrario and Panos Kanavos
(R)Evolution

Y 2006
Version 1.0

Y 2013
Version 2.0

Data collection & Monitoring

Therapeutic area’ approach data collection

Accreditation pyramidal system

Regions
Health managers
Pharma companies

Farmaci sottoposti a monitoraggio

Programmi generali:
- Farmaci antincoagulanti
- Farmaci eritropoietici
- Farmaci per la prevenzione della trombosi
- Farmaci anti-HIV
- Farmaci antitumorali
- Farmaci antidiabetici
- Farmaci cardiovascolari

Progetti specifici:
- Tysabri
- ADHD
- Xolar
g - Xigris

Con il Registro dei farmaci e monitoraggio l’Agenzia Italiana del Farmaco (AIFA) intende mettere a disposizione degli operatori sanitari un punto di accesso unificato ai progetti di monitoraggio che sono richiesti, adottare, complementi o determinanti di intervento in concreto per l’esecuzione delle specifiche attività mediche (in base alle procedure definite di riferimento degli_servizi).

Il Registro unificato intende porre come strumento innovativo di comunicazione e assistenza per i professionisti, per una efficace semplificazione degli interventi di controllo, per l’adozione di un processo virtuale in grado di supportare una ampia area clinica e sanitaria della popolazione.
> 850,000 Patients
> 24,000 physicians and >1,300 pharmacists
32 MAH
~ 900 Health managers & 48 Regional responsible Agents
The Italian Databases and HCV Treatment Costs

- New treatments DAAs are able to eradicate the infection in almost all patients

**But...**

- High prevalence of the infection in Italy (about 2.6 to 3%);
- High cost treatment proposed;
- Unsustainability spending for our NHS;
- Although sofosbuvir/ledipasvir results could be cost-effective in several subgroups population, problem of economic sustainability remains!
Italian Medicines Agency Strategy for HCV

- Permanent national working group on HCV
- Compassionate use programs > 2,500 pts treated
- Joint negotiation and procurement initiatives with other European countries
- Prioritization program based on clinical urgency criteria

Safeguarding equity/homogeneity of drug access by guaranteeing the sustainability of the system.
**Disease Criteria to access treatments**

**Criterion 1** - Patients with cirrhosis in Child class A or B and/or HCC with complete response to therapy resistentive surgical or locoregional not candidates for liver transplantation in which the liver disease significantly affects prognosis.

**Criterion 2** - Recurrent hepatitis HCV RNA-positive liver transplant patients in clinically stable and with optimal levels of immunosuppression.

**Criterion 3** - Chronic hepatitis with severe HCV-related extrahepatic manifestations (cryoglobulinemic syndrome with organ damage, B-cell lymphoproliferative syndromes).

**Criterion 4** - Chronic hepatitis with fibrosis METAVIR F3 (or corresponding Ishak).

**Criterion 5** - In the list for liver transplantation with cirrhosis MELD <25 and/or HCC within the Milan criteria with the possibility of waiting in a list of at least 2 months.

**Criterion 6** - Chronic hepatitis after solid organ transplantation (not liver) or marrow fibrosis METAVIR ≥2 (or corresponding Ishack).

**Criterion 7** - Chronic hepatitis with fibrosis METAVIR F0-F2 (or corresponding Ishak).
The total number of treatments as of Feb 2016 is **34.487**.
Criterion 1: 24.453; Criterion 4: 6.726; Criterion 2: 1.280; Criterion 3: 1.333; Criterion 5: 226; Criterion 6: 130; Criterion 7: 347.
Costs of HCV Drugs in Italy

Monitoring the number of patients at individual level allowed AIFA to negotiate prices by precise price/volume discount confidential contracts. These were linked to product specific managed entry agreements, mainly based on the high prevalence of this pathology in Italy but also on real life payment by result.

Prices obtained are the lowest in the EU, Japan and North America
The incretin-mimetic and incretin-enhancer AIFA Registry was the first example of a “dirty” monitoring tool in a highly prevalent disease largely managed by general practitioners (GPs).

We analysed 75,283 pts with type 2 diabetes treated with exenatide, sitagliptin, or vildagliptin over two years.

Result: In real world prescriptions, incretins have been mostly used off-label. When appropriately utilized, incretins showed results in line with those in registration trials.
AI FA Databases of drugs for Multiple Sclerosis
This registry has been active from 2007 to 2012

6.304 patients recorded; 99% evaluated; 97% eligible and 88% treated.

Data of follow up for 3.539 (42%) patients.
Characteristics at baseline, efficacy outcome in the general population and in the highly active MS subcluster are analyzed in comparison to the Affirm study.

12 patients have been diagnosed and confirmed with PML.
The National Medicines Observatory (OsMed) and the use of Antidepressants

Osmed is the largest data warehouse from unselected population in the world, with almost 40 million people in all age groups.

Al FA started a study in collaboration with MGH (Maurizio Fava et al.) on the evaluation of real-life treatment-resistant depression on approximately 450,000 patients selected from Osmed.
Study on Resistant Depression: Methods

An AD utilization index (resistance class 0, 1, 2, 3 and > 4) was calculated as the number of antidepressants (by ATC codes) treatment courses for at least 6 weeks (1 point = 1 ATC treatment course).

Patients (age range, gender and comorbidity index) for each resistance class have been followed up for two years after the index prescription.

Distribution by comorbidity index as well as costs will be calculated for each resistance class over a 12 months period after the two years of follow up*.

* Manuscript in preparation
Conclusions: Italian Registries and Clinical Trials

1. Accelerate access of drugs to subclusters of patients;
2. Prevent exclusion of drugs with potential efficacy;
3. Early exclusion of drugs with safety issues;
4. Real world data generation;
5. Contain NHS expenditure optimizing allocation of resources and the sustainability of the system;
6. Use of these resources in clinical trials?